Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, scPharmaceuticals Inc’s stock clocked out at $3.40, down -5.82% from its previous closing price of $3.61. In other words, the price has decreased by -$5.82 from its previous closing price. On the day, 1.16 million shares were traded. SCPH stock price reached its highest trading level at $3.5 during the session, while it also had its lowest trading level at $3.2.
Ratios:
To gain a deeper understanding of SCPH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.89 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 1.71 whereas as Long-Term Debt/Eq ratio is at 1.70.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 07, 2023, initiated with a Buy rating and assigned the stock a target price of $20.
On December 01, 2022, Cowen started tracking the stock assigning a Outperform rating and target price of $25.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’24 when ORBIMED ADVISORS LLC bought 500,000 shares for $4.00 per share. The transaction valued at 2,000,000 led to the insider holds 5,806,670 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SCPH now has a Market Capitalization of 170136352. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.62 while its Price-to-Book (P/B) ratio in mrq is 5.54.
Stock Price History:
The Beta on a monthly basis for SCPH is 0.10, which has changed by -0.3797251 over the last 52 weeks, in comparison to a change of 0.27870452 over the same period for the S&P500. Over the past 52 weeks, SCPH has reached a high of $6.71, while it has fallen to a 52-week low of $3.08. The 50-Day Moving Average of the stock is -13.90%, while the 200-Day Moving Average is calculated to be -25.19%.
Shares Statistics:
It appears that SCPH traded 379.48K shares on average per day over the past three months and 383760 shares per day over the past ten days. A total of 50.04M shares are outstanding, with a floating share count of 34.52M. Insiders hold about 31.01% of the company’s shares, while institutions hold 61.37% stake in the company. Shares short for SCPH as of 1732838400 were 5713041 with a Short Ratio of 15.05, compared to 1730332800 on 4128838. Therefore, it implies a Short% of Shares Outstanding of 5713041 and a Short% of Float of 12.9.
Earnings Estimates
Investors are keenly observing as 3.0 analysts analyze and rate the current performance of scPharmaceuticals Inc (SCPH) in the stock market.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.17 and low estimates of -$0.38.
Analysts are recommending an EPS of between -$1.49 and -$2.02 for the fiscal current year, implying an average EPS of -$1.78. EPS for the following year is -$1.08, with 3.0 analysts recommending between -$0.95 and -$1.3.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $12.18M. It ranges from a high estimate of $12.8M to a low estimate of $11.8M. As of the current estimate, scPharmaceuticals Inc’s year-ago sales were $6.1MFor the next quarter, 6 analysts are estimating revenue of $14.43M. There is a high estimate of $15.5M for the next quarter, whereas the lowest estimate is $12.8M.
A total of 6 analysts have provided revenue estimates for SCPH’s current fiscal year. The highest revenue estimate was $37M, while the lowest revenue estimate was $35.9M, resulting in an average revenue estimate of $36.33M. In the same quarter a year ago, actual revenue was $13.59MBased on 6 analysts’ estimates, the company’s revenue will be $84.09M in the next fiscal year. The high estimate is $96.4M and the low estimate is $74M.
